IP Library Granted Patent US 9,738,651
Granted Patent B2
US 9,738,651 · App. 14/775,766 · Granted Aug 22, 2017

CARM1 inhibitors and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,738,651
App. No.
14/775,766
Granted
Aug 22, 2017
Kind
B2
Abstract

Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R 1 , R 1a , R 2a , R 2b , R 2c , R 2d , are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula (II) wherein L 2 , R 13 , G 8 , G 10 , G 11 , and G 12 are as defined herein. Compounds of the present invention are useful for inhibiting CARM1 activity. Methods of using the compounds for treating CARM1-mediated disorders are also described.

Claims (75)

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof;

wherein:

X is —O—, —S—, or —CH 2 —;

R 1 and R 1a are each independently hydrogen or optionally substituted C 1-4 aliphatic, or R 1 and R 1a may be joined to form a substituted or unsubstituted heterocyclic, or substituted or unsubstituted heteroaryl ring;

each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, halogen, —CN, —NO 2 , —C(═O)R A2 , —C(═O)OR A2 , —C(═O)N(R A2 ) 2 , —OR A2 , —SR A2 , —N(R A2 ) 2 , —S(═O)R A2 , —S(═O) 2 R A2 , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl, wherein each instance of R A2 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R A2 groups attached to the same nitrogen atom are joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring;

Ring HET is a 6-membered monocyclic heteroaryl ring system of the Formula:

each instance of R 8 , R 10 , R 11 , and R 12 is independently selected from the group consisting of hydrogen, halo, —CN, —NO 2 , —C(═O)R′, —C(═O)OR′, —C(═O)N(R′) 2 , optionally substituted alkyl, optionally substituted C 3-4 cycloalkyl, and -L 1 -R 3 ;

each instance of R′ is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R′ groups attached to the same nitrogen are joined to form an optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring;

each instance of L 1 and L 2 is independently a bond, —O—, —N(R L )—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R L )—, —C(O)N(R L )N(R L )—, —OC(O)—, —OC(O)N(R L )—, —NR L C(O)—, —NR L C(O)N(R L )—, —NR L C(O)N(R L )N(R L )—, —NR L C(O)O—, —SC(O)—, —C(═NR L )—, —C(═NNR L )—, —C(═NOR L )—, —C(═NR L )N(R L )—, —NR L C(═NR L )—, —C(S)—, —C(S)N(R L )—, —NR L C(S)—, —S(O)—, —OS(O) 2 —, —S(O) 2 O—, —SO 2 —, —N(R L )SO 2 —, —SO 2 N(R L )—, —N(R L )SO 2 N(R L )—, or an optionally substituted C 1-10 saturated or unsaturated hydrocarbon chain, wherein one or more moieties selected from the group consisting of —O—, —N(R L )—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R L )—, —C(O)N(R L )N(R L )—, —OC(O)—, —OC(O)N(R L )—, —NR L C(O)—, —NR L C(O)N(R L )—, —NR L C(O)N(R L )N(R L ), —NR L C(O)O—, —SC(O)—, —C(═NR L )—, —C(═NNR L )—, —C(═NOR L )—, —C(═N R L )N(R L )—, —NR L C(═NR L )—, —C(S)—, —C(S)N(R L )—, —NR L C(S)—, —S(O)—, —OS(O) 2 —, —S(O) 2 O—, —SO 2 —, —N(R L )SO 2- , —SO 2 N(R L )—, and —N(R L )SO 2 N(R L )— is optionally and independently present between two carbon atoms of the hydrocarbon chain, and optionally and independently present at one or both ends of the hydrocarbon chain;

each R L is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group, or R L and R 3 taken together form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring, or R L and R 13 taken together form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring;

R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, provided when R 3 is hydrogen, then L 1 is not a bond; and

R 13 is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

2. The compound of claim 1 , wherein X is —O—.

3. The compound of claim 1 , wherein X is —S— or —CH 2 —.

4. The compound of claim 1 , wherein Ring HET is:

5. The compound of claim 1 , wherein Ring HET is:

6. The compound of claim 1 , wherein Ring HET is:

7. The compound of claim 1 , wherein R 1 is hydrogen, methyl, ethyl, n-propyl, isopropyl, or cyclopropyl, and R 1a is hydrogen.

8. The compound of claim 1 , wherein R 2a , R 2b , and R 2d are hydrogen.

9. The compound of claim 1 , wherein at least one of R 2a , R 2b , R 2c , and R 2d is halogen.

10. The compound of claim 1 , wherein L 2 is a bond, —N(R L )—, —NR L C(O)O—, —NR L C(O)N(R L )—, —N(R L )SO 2 N(R L )—, —NR L —(CH 2 ) x —C(O)O—, —NR L —(CH 2 ) x —O—, —NR L C(O)N(R L )—, —NR L —(CH 2 ) x —, —(CH 2 ) x —NR L —, —NR L C(O)O(CH 2 ) x —, —NR L C(O)NR L (CH 2 ) x —, or —NR L (CH 2 ) x NR L C(O)—, wherein x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

11. The compound of claim 1 , wherein R 13 is selected from the group consisting of:

wherein

each independently represents a single or double bond;

m is 0, 1, 2, or 3;

each instance of R 13A is independently hydroxyl, substituted hydroxyl, thiol, substituted thiol, amino, substituted amino, carbonyl, sulfonyl, sulfinyl, —CN, —NO 2 , halogen, or optionally substituted alkyl, or two R 13A groups are joined to form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl ring, or R 13A and R 13B group are joined to form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl ring; and

R 3B and R 13B are independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group.

12. The compound of claim 1 , wherein Ring HET comprises a group -L 1 -R 3 attached thereto.

13. The compound of claim 12 , wherein L 1 is a bond, —N(R L )—, —NR L C(O)O—, —NR L C(O)N(R L )—, —N(R L )SO 2 N(R L )—, —NR L —(CH 2 ) x —C(O)O—, —NR L —(CH 2 ) x —O—, —NR L C(O)N(R L )—, —NR L —(CH 2 ) x —, —(CH 2 ) x —NR L —, —NR L C(O)O(CH 2 ) x —, —NR L C(O)NR L (CH 2 ) x —, or —NR L (CH 2 ) x NR L C(O)—, wherein x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

14. The compound of claim 12 , wherein R 3 is selected from the group consisting of:

wherein:

each instance of independently represents a single or double bond;

n is 0, 1, 2, or 3;

each instance of R 3A is independently hydroxyl, substituted hydroxyl, thiol, substituted thiol, amino, substituted amino, carbonyl, sulfonyl, sulfinyl, —CN, —NO 2 , halogen, or optionally substituted alkyl, or two R 3A groups are joined to form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl ring, or R 3A and R 3B groups are joined to form an optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl ring; and

R 3B is hydrogen, optionally substituted alkyl, or a nitrogen protecting group.

15. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

16. A kit or packaged pharmaceutical comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and instructions for use thereof.

17. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof;

wherein:

X is —O—, —S—, or —CH 2 —;

R 1 and R 1a are each independently hydrogen or optionally substituted C 1-4 aliphatic, or R 1 and R 1a may be joined to form a substituted or unsubstituted heterocyclic, or substituted or unsubstituted heteroaryl ring;

each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, halogen, —CN, —NO 2 , —C(═O)R A2 , —C(═O)OR A2 , —C(═O)N(R A2 ) 2 , —OR A2 , —SR A2 , —N(R A2 ) 2 , —S(═O)R A2 , —S(═O) 2 R A2 , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl, wherein each instance of R A2 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R A2 groups attached to the same nitrogen atom are joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring;

Ring HET is a 6-membered monocyclic heteroaryl ring system of the Formula:

wherein:

G 8 is C—R 8 or N;

G 10 is C—R 10 or N;

G 11 is C—R 11 or N;

G 12 is C—R 12 or N;

provided at least one instance of G 8 , G 10 , G 11 , or G 12 is N;

each instance of R 8 , R 10 , R 11 , and R 12 is independently selected from the group consisting of hydrogen, halo, —CN, —NO 2 , —C(═O)R′, —C(═O)OR′, —C(═O)N(R′) 2 , optionally substituted alkyl, optionally substituted C 3-4 cycloalkyl, and -L 1 -R 3 ;

each instance of R′ is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R′ groups attached to the same nitrogen are joined to form an optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring;

each instance of L 1 and L 2 is independently a bond, —O—, —N(R L )—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R L )—, —C(O)N(R L )N(R L )—, —OC(O)—, —OC(O)N(R L )—, —NR L C(O)—, —NR L C(O)N(R L )—, —NR L C(O)N(R L )N(R L )—, —NR L C(O)O—, —SC(O)—, —C(═NR L )—, —C(═NNR L )—, —C(═NOR L )—, —C(═NR L )N(R L )—, —NR L C(═NR L )—, —C(S)—, —C(S)N(R L )—, —NR L C(S)—, —S(O)—, —OS(O) 2 —, —S(O) 2 O—, —SO 2 —, —N(R L )SO 2 —, —SO 2 N(R L )—, —N(R L )SO 2 N(R L )—, or an optionally substituted C 1-10 saturated or unsaturated hydrocarbon chain, wherein one or more moieties selected from the group consisting of —O—, —N(R L )—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R L )—, —C(O)N(R L )N(R L )—, —OC(O)—, —OC(O)N(R L )—, —NR L C(O)—, —NR L C(O)N(R L )—, —NR L C(O)N(R L )N(R L )—, —NR L C(O)O—, —SC(O)—, —C(═NR L )—, —C(═NNR L )—, —C(═NOR L )—, —C(═NR L )N(R L )—, —NR L C(═NR L )—, —C(S)—, —C(S)N(R L )—, —NR L C(S)—, —S(O)—, —OS(O) 2 —, —S(O) 2 O—, —SO 2 —, —N(R L )SO 2- , —SO 2 N(R L )—, and —N(R L )SO 2 N(R L )— is optionally and independently present between two carbon atoms of the hydrocarbon chain, and optionally and independently present at one or both ends of the hydrocarbon chain;

each R L is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group, or R L and R 3 taken together form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring, or R L and R 13 taken together form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring;

R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, or aryl unsubstituted or substituted with one or more substituents independently selected from the group consisting of halogen, —CN, —NO 2 , —N 3 , —SO 2 H, —SO 3 H, —OH, —OR aa , —N(R bb ) 2 , —SH, —SR aa , —C(═O)R aa , —CO 2 H, —CHO, —CO 2 R aa , —OC(═O)R aa , —OCO 2 R aa , —C(═O)N(R bb ) 2 , —OC(═O)N(R bb ) 2 , C 1-4 alkyl, C 1-4 perhaloalkyl, C 2-4 alkenyl, and C 2-4 alkynyl, provided when R 3 is hydrogen, then L 1 is not a bond; and

R 13 is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted heteroaryl, or aryl unsubstituted or substituted with one or more substituents independently selected from the group consisting of halogen, —CN, —NO 2 , —N 3 , —SO 2 H, —SO 3 H, —OH, —OR aa , —N(R bb ) 2 , —SH, —SR aa , —C(═O)R aa , —CO 2 H, —CHO, —CO 2 R aa , —OC(═O)R aa , —OCO 2 R aa , —C(═O)N(R bb ) 2 , —OC(═O)N(R bb ) 2 , C 1-4 alkyl, C 1-4 perhaloalkyl, C 2-4 alkenyl, and C 2-4 alkynyl;

wherein:

each instance of R aa is, independently, C 1-4 alkyl; and

each instance of R bb is, independently, hydrogen or C 1-4 alkyl, or two R bb groups are joined to form a 3-6 membered heterocyclyl or 5-6 membered heteroaryl ring;

provided the compound is not:

18. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof;

wherein:

X is —O—, —S—, or —CH 2 —;

R 1 and R 1a are each independently hydrogen or optionally substituted C 1-4 aliphatic, or R 1 and R 1a may be joined to form a substituted or unsubstituted heterocyclic, or substituted or unsubstituted heteroaryl ring;

each of R 2a , R 2b , R 2c , and R 2d is independently hydrogen, halogen, —CN, —NO 2 , —C(═O)R A2 , —C(═O)OR A2 , —C(═O)N(R A2 ) 2 , —OR A2 , —SR, —N(R A2 ) 2 , —S(═O)R A2 , —S(═O) 2 R A2 , optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, or optionally substituted heterocyclyl, wherein each instance of R A2 is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R A2 groups attached to the same nitrogen atom are joined to form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring;

Ring HET is a 6-membered monocyclic heteroaryl ring system of the Formula:

each instance of R 8 , R 10 , R 11 , and R 12 is independently selected from the group consisting of hydrogen, halo, —CN, —NO 2 , —C(═O)R′, —C(═O)OR′, —C(═O)N(R′) 2 , optionally substituted alkyl, optionally substituted C 3-4 cycloalkyl, and -L 1 -R 3 ;

each instance of R′ is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R′ groups attached to the same nitrogen are joined to form an optionally substituted heterocyclyl ring or optionally substituted heteroaryl ring;

each instance of L 1 and L 2 is independently a bond, —O—, —N(R L )—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R L )—, —C(O)N(R L )N(R L )—, —OC(O)—, —OC(O)N(R L )—, —NR L C(O)—, —NR L C(O)N(R L )—, —NR L C(O)N(R L )N(R L )—, —NR L C(O)O—, —SC(O)—, —C(═NR L )—, —C(═NNR L )—, —C(═NOR L )—, —C(═NR L )N(R L )—, —NR L C(═NR L )—, —C(S)—, —C(S)N(R L )—, —NR L C(S)—, —S(O)—, —OS(O) 2 —, —S(O) 2 O—, —SO 2 —, —N(R L )SO 2 —, —SO 2 N(R L )—, —N(R L )SO 2 N(R L )—, or an optionally substituted C 1-10 saturated or unsaturated hydrocarbon chain, wherein one or more moieties selected from the group consisting of —O—, —N(R L )—, —S—, —C(O)—, —C(O)O—, —C(O)S—, —C(O)N(R L )—, —C(O)N(R L )N(R L )—, —OC(O)—, —OC(O)N(R L )—, —NR L C(O)—, —NR L C(O)N(R L )—, —NR L C(O)N(R L )N(R L )—, —NR L C(O)O—, —SC(O)—, —C(═NR L )—, —C(═NNR L )—, —C(═NOR L )—, —C(═NR L )N(R L )—, —NR L C(═NR L )—, —C(S)—, —C(S)N(R L )—, —NR L C(S)—, —S(O)—, —OS(O) 2 —, —S(O) 2 O—, —SO 2 —, —N(R L )SO 2- , —SO 2 N(R L )—, and —N(R L )SO 2 N(R L )— is optionally and independently present between two carbon atoms of the hydrocarbon chain, and optionally and independently present at one or both ends of the hydrocarbon chain;

each R L is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group, or R L and R 3 taken together form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring, or R L and R 13 taken together form an optionally substituted heterocyclyl or optionally substituted heteroaryl ring;

R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, provided when R 3 is hydrogen, then L 1 is not a bond; and

R 13 is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

provided the compound is not:

Assignments (3)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME: 051057/0848 Recorded Aug 13, 2022
From: BIOPHARMA CREDIT PLC
To: EPIZYME, INC.
Reel/Frame 061165/0501 →
SECURITY INTEREST Recorded Nov 19, 2019
From: EPIZYME, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051057/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2015
From: CHESWORTH, RICHARD; MORADEI, OSCAR MIGUEL; SHAPIRO, GIDEON; JIN, LEI; BABINE, ROBERT E.
To: EPIZYME, INC.
Reel/Frame 036618/0398 →